CytomX Therapeutics (CTMX) Total Current Liabilities (2014 - 2026)

CytomX Therapeutics' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $34.0 million for Q1 2026.

• Quarterly Total Current Liabilities fell 32.23% year-over-year to $34.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.0 million (down 32.23% YoY) and the FY2025 annual result came in at $46.6 million, down 45.65% from the prior year.
• Total Current Liabilities was $34.0 million for Q1 2026 at CytomX Therapeutics, down from $46.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $155.9 million in Q4 2023 and bottomed at $34.0 million in Q1 2026.
• A 5-year average of $103.4 million and a median of $119.2 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 95.98% — and 2025, when it sank 72.54%.
• CytomX Therapeutics' Total Current Liabilities stood at $152.6 million in 2022, then rose by 2.17% to $155.9 million in 2023, then plunged by 44.99% to $85.8 million in 2024, then tumbled by 45.65% to $46.6 million in 2025, then slipped by 27.01% to $34.0 million in 2026.
• Business Quant data shows CTMX's Total Current Liabilities at $34.0 million in Q1 2026, $46.6 million in Q4 2025, and $41.0 million in Q3 2025.